$205.00 with 18 percent savings
List Price: $250.00

The List Price is the suggested retail price of a new product as provided by a manufacturer, supplier, or seller. Except for books, Amazon will display a List Price if the product was purchased by customers on Amazon or offered by other retailers at or above the List Price in at least the past 90 days. List prices may not necessarily reflect the product's prevailing market price.
Learn more
FREE Returns
Only 1 left in stock (more on the way).
$$205.00 () Includes selected options. Includes initial monthly payment and selected options. Details
Price
Subtotal
$$205.00
Subtotal
Initial payment breakdown
Shipping cost, delivery date, and order total (including tax) shown at checkout.
Ships from
Amazon.com
Ships from
Amazon.com
Sold by
Amazon.com
Sold by
Amazon.com
Returns
Eligible for Return, Refund or Replacement within 30 days of receipt
Eligible for Return, Refund or Replacement within 30 days of receipt
This item can be returned in its original condition for a full refund or replacement within 30 days of receipt.
Read full return policy
Returns
Eligible for Return, Refund or Replacement within 30 days of receipt
This item can be returned in its original condition for a full refund or replacement within 30 days of receipt.
Read full return policy
Payment
Secure transaction
Your transaction is secure
We work hard to protect your security and privacy. Our payment security system encrypts your information during transmission. We don’t share your credit card details with third-party sellers, and we don’t sell your information to others. Learn more
Payment
Secure transaction
We work hard to protect your security and privacy. Our payment security system encrypts your information during transmission. We don’t share your credit card details with third-party sellers, and we don’t sell your information to others. Learn more
Amazon book clubs early access
Loading your book clubs
There was a problem loading your book clubs. Please try again.
Not in a club? Learn more
Amazon book clubs early access

Join or create book clubs

Choose books together

Track your books
Bring your club to Amazon Book Clubs, start a new book club and invite your friends to join, or find a club that’s right for you for free.
Explore Amazon Book Clubs
Kindle app logo image

Download the free Kindle app and start reading Kindle books instantly on your smartphone, tablet, or computer - no Kindle device required.

Read instantly on your browser with Kindle for Web.

Using your mobile phone camera - scan the code below and download the Kindle app.

QR code to download the Kindle App

Cytotoxic Payloads for Antibody–Drug Conjugates (Drug Discovery, 71) 1st Edition

by David E Thurston (Editor), Paul J M Jackson (Editor)
5.0 5.0 out of 5 stars 1 rating
See all formats and editions
{"desktop_buybox_group_1":[{"displayPrice":"$205.00","priceAmount":205.00,"currencySymbol":"$","integerValue":"205","decimalSeparator":".","fractionalValue":"00","symbolPosition":"left","hasSpace":false,"showFractionalPartIfEmpty":true,"offerListingId":"2LxqHiwIikr5vZoIkAmayF3Anvni5moMeEHzlGo0Ce04yYFKmjrGuhoxHYLJetvf1IBNwtGfzAqodhQu1I8MUr3%2F4CcZV%2FvtBAuZleP2hXpkE%2FTMzwLtesD55l5S8UDaT3z7j9KyVcN2sIh4k1zrAA%3D%3D","locale":"en-US","buyingOptionType":"NEW","aapiBuyingOptionIndex":0}]}

Purchase options and add-ons

Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab ozogamicin (Besponsa™), gemtuzumab ozogamicin (Mylotarg™) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many.

The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity.

Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.

Read more Read less
Previous page
  1. ISBN-10
    1788010779
  2. ISBN-13
    978-1788010771
  3. Edition
    1st
  4. Publisher
    Royal Society of Chemistry
  5. Publication date
    July 15, 2019
  6. Language
    English
  7. Dimensions
    6.5 x 1.5 x 9.75 inches
  8. Print length
    502 pages
  9. See all details
Next page
Amazon First Reads | Editors' picks at exclusive prices

Editorial Reviews

Review

Plan on having this sitting on your desk shelf as the definitive guide to ADC payloads for the next 5-10 years. -- Justin Sweeley, Novasep ― 5 Things You Need To Know This Week About ADCs – July 27, 2019 ADCReview

From the Inside Flap

Antibody drug conjugates (ADCs) represent an exciting and promising area of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla ), brentuximab vedotin (Adcetris ), inotuzumab ozogamicin (Besponsa ), gemtuzumab ozogamicin (Mylotarg ) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many.

The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity.

Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.

Product details

  • Publisher ‏ : ‎ Royal Society of Chemistry; 1st edition (July 15, 2019)
  • Language ‏ : ‎ English
  • Hardcover ‏ : ‎ 502 pages
  • ISBN-10 ‏ : ‎ 1788010779
  • ISBN-13 ‏ : ‎ 978-1788010771
  • Item Weight ‏ : ‎ 2.01 pounds
  • Dimensions ‏ : ‎ 6.5 x 1.5 x 9.75 inches
  • Customer Reviews:
    5.0 5.0 out of 5 stars 1 rating

Customer reviews

5 out of 5 stars
5 out of 5
1 global rating

No customer reviews

There are 0 customer reviews and 1 customer rating.